Sense anticipates launching Veros Covid-19 in Europe this quarter, initially in Ireland, Benelux and the Nordic regions
This decision does not impact the ongoing AReSVi 006 phase III trial for RSV older adults.
Nirsevimab is the first investigational long-acting antibody designed to protect all infants for the respiratory syncytial virus season with a single dose
Up to 100 million mRNA vaccine doses could be produced in Australia each year
RT-PCR test detects and differentiates SARS-CoV-2, influenza A, influenza B and respiratory syncytial virus
Three new molecular diagnostic test panels for influenza and other common respiratory illnesses can be run together or alone using one patient sample
The collaboration will support Canada with direct access to rapid pandemic response capabilities
Subscribe To Our Newsletter & Stay Updated
